Zafgen's Phase III trial of obesity drug Beloranib shows efficacy

Biopharmaceutical company Zafgen announced that the Phase III trial of its experimental obesity drug Beloranib in Prader-Willi syndrome (PWS) has achieved co-primary efficacy endpoints.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news